A28 Therapeutics, a privately-held, clinical-stage biopharmaceutical company focused on the development of cancer treatments, has announced that its AT-101 lytic ...
The NY Journals pride themselves on assembling a proficient and dedicated team comprising seasoned journalists and editors. This collective commitment drives us to provide our esteemed readership with nothing short of the most comprehensive, accurate, and captivating news coverage available.
Transcending the bounds of New York City to encompass a broader scope, we ensure that our audience remains well-informed and engaged with the latest developments, both locally and beyond.
© 2024 The New York Journals. All Rights Reserved.
